June 2018

26 Jun
34

Apellis Pharmaceuticals Announces First Patient Enrolled in Phase 3 APL-2 Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Soliris™

In All, Portfolio

CRESTWOOD, Ky. and WALTHAM, Mass. —  Apellis Pharmaceuticals, Inc.  (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that it has commenced its PEGASUS Phase 3 trial assessing the safety and…

26 Jun
30

Apellis Pharmaceuticals Provides Update on Two Phase Ib Trials for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

In All, Portfolio

Severely anemic patients with PNH on treatment with Soliris™ can become transfusion-free with improved hemoglobin when switched to APL-2 monotherapy. Treatment-naïve patients with PNH show clinically meaningful improvements for all hematological parameters when treated with APL-2.   CRESTWOOD, Ky. and WALTHAM, Mass. —  Apellis Pharmaceuticals, Inc.  (Nasdaq:APLS),…

25 Jun
32

NodThera Secures £28 million ($40 million) Series A Financing

In All, Portfolio

NodThera discovers and develops next generation NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation Cambridge, UK, 25 June 2018 – NodThera, a biotechnology company focused on the discovery and development of next generation NLRP3 inflammasome inhibitors for the treatment of diseases…